In updated results from the RADIANT trials of treatment for advanced neuroendocrine tumors, everolimus provided a 2.4-fold increase in median progressionfree survival (PFS) for patients with pancreatic neuroendocrine tumors. In combination with the long-acting formulation of the somatostatin analog octreotide (Sandostatin LAR) in patients with carcinoid syndrome, however, the benefit was more questionable. The updates were reported at the 2011 Gastrointestinal Cancers Symposium. The phase III RADIANT-3 trial randomly...